Triple approach strategy for patients with locally advanced pancreatic carcinoma

Abstract

BackgroundRadiofrequency ablation (RFA) is a relatively new technique, applied to metastatic solid tumours which, in recent studies, has been shown to be feasible and safe on locally advanced pancreatic carcinoma (LAPC). RFA can be combined with radio‐chemotherapy (RCT) and intra‐arterial plus systemic chemotherapy (IASC). The aim of this study was to investigate the impact on the prognosis of a multimodal approach to LAPC and define the best timing of RFA. MethodsThis is a retrospective observational study of patients who have consecutively undergone RFA associated with multiple adjuvant approaches. ResultsBetween February 2007 and December 2011, 168 consecutive patients were treated by RFA, of which 107 were eligible for at least 18 months of follow‐up. Forty‐seven patients (group 1) underwent RFA as an up‐front treatment and 60 patients as second treatment (group 2) depending on clinician choice. The median overall survival (OS) of the whole series was 25.6 months: 14.7 months in the group 1 and 25.6 months in the group 2 (P = 0.004). Those patients who received the multimodal treatment (RFA, RCT and IASC‐triple approach strategy) had an OS of 34.0 months. ConclusionsThe multimodal approach seems to be feasible and associated with an improved longer survival rate.